Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bhattacharjee named as...

    Bhattacharjee named as generics group head by Teva

    Written by supriya kashyap kashyap Published On 2016-12-07T12:19:42+05:30  |  Updated On 7 Dec 2016 12:19 PM IST
    Bhattacharjee named as generics group head by Teva

    Teva Pharmaceutical Industries, the world's biggest generic drugmaker, has appointed Dipankar Bhattacharjee as chief executive for its global generic medicines group, replacing Siggi Olafsson.


    Bhattacharjee, who has served as CEO of Teva Generics Europe since April 2013, will replace Olafsson, who will retire at the end of the first quarter of 2017. Bhattacharjee will be based in the United States.


    As CEO of Teva Generics Europe, Bhattacharjee "has a proven track record of improving revenues and profitability, significantly increasing operating profit margins in the European generics business," Teva said in a statement on Monday.


    Launch delays for some drugs led Israel-based Teva last month to trim forecasts for earnings and revenues this year.


    Its share price is down by 44 percent in 2016, despite completing a $40.5 billion purchase of Allergan plc's Actavis generic drug business in August.


    Teva on Monday reaffirmed its full-year 2016 outlook of revenues of $21.6-$21.9 billion and adjusted earnings per share of $5.10-$5.20.


    Revenues in the fourth quarter are expected to be $6.2-$6.5 billion and adjusted EPS $1.34-$1.44, Teva said.


    Teva expects to provide its 2017 outlook in January.


    "As we continue to focus on integrating and realizing the value of the Actavis Generics transaction, which is progressing according to plan, Dipankar and his team will focus on generating organic growth through new launches and replenishing the pipeline," Teva CEO Erez Vigodman said.


    Bhattacharjee joined Teva as general manager of Teva UK in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles.

    AllerganDipankar BhattacharjeeErez VigodmanSiggi OlafssonTeva
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok